Inosine pranobex immunotherapy for cervical HPV positives | IDR - Dove Medical Press
Inosine pranobex immunotherapy for cervical HPV positives | IDR - Dove Medical Press Inosine pranobex immunotherapy for cervical HPV positives | IDR - Dove Medical Press Posted: 02 Jun 2021 12:00 AM PDT Introduction To date, >200 human papillomavirus (HPV) types have been detected. 1–3 The most common HPV transmission route is sexual contact. 2 Sexually active individuals will acquire ≥ 1 anogenital HPV genotype at some point in their lives. 4 Sensitive PCR monitoring has indicated that most HPV infections are cleared by the immune system and disappear within 1–2 y without clinical complications. 5 , 6 Epidemiological evidence for HPV carcinogenicity was first presented by zurHausen in 1983 and accepted in 1995 by the International Agency for Cancer Research (IARC) of the World Health Organization (WHO). 4 HPV carcinogenicity was first established for cervical precancers and cancers. Cervical carcinogenesis is a multi-step process ...